Analysts at Janney Montgomery Scott started coverage on shares of Uniqure (NASDAQ:QURE) in a research report issued on Wednesday, January 3rd, Marketbeat.com reports. The brokerage set a “buy” rating and a $25.00 price target on the biotechnology company’s stock. Janney Montgomery Scott’s price objective would suggest a potential upside of 42.13% from the stock’s previous close.
Other research analysts have also recently issued reports about the company. Zacks Investment Research cut Uniqure from a “hold” rating to a “sell” rating in a research report on Wednesday, October 18th. HC Wainwright set a $28.00 price objective on Uniqure and gave the company a “buy” rating in a report on Thursday, December 7th. Leerink Swann raised their price objective on Uniqure from $19.00 to $26.00 in a report on Tuesday, November 7th. Oppenheimer reissued a “hold” rating on shares of Uniqure in a report on Friday, November 24th. Finally, ValuEngine raised Uniqure from a “sell” rating to a “hold” rating in a research note on Tuesday, December 26th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $20.00.
Uniqure (NASDAQ:QURE) opened at $17.59 on Wednesday. Uniqure has a 12 month low of $4.72 and a 12 month high of $21.35. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.64 and a current ratio of 3.64.
In related news, CEO Matthew C. Kapusta sold 21,690 shares of the business’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $19.87, for a total value of $430,980.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Christian Klemt sold 5,093 shares of the business’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $20.13, for a total value of $102,522.09. The disclosure for this sale can be found here. Insiders sold a total of 32,647 shares of company stock worth $651,545 in the last quarter. Company insiders own 0.73% of the company’s stock.
Several large investors have recently added to or reduced their stakes in QURE. JPMorgan Chase & Co. boosted its position in shares of Uniqure by 33.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock worth $362,000 after acquiring an additional 14,659 shares in the last quarter. FMR LLC boosted its position in shares of Uniqure by 4.1% during the 2nd quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock worth $9,656,000 after acquiring an additional 61,650 shares in the last quarter. Mangrove Partners acquired a new stake in shares of Uniqure in the 2nd quarter valued at about $247,000. Finally, OxFORD Asset Management LLP acquired a new stake in shares of Uniqure in the 3rd quarter valued at about $399,000. 24.87% of the stock is owned by institutional investors and hedge funds.
Uniqure Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.